Figure 1.
Serum logarithm of NT-proBNP levels during a 24-month follow-up.
Measurements represent the median value at basal (1), stage I (2) and stage II (3). NT-proBNP, N-terminal pro-brain natriuretic peptide levels; stage I, 12-month follow-up; stage II, 24-month follow-up. **p<0.01 with respect to basal levels.
Table 1.
Clinical characteristics of patients with essential hypertension and left ventricular hypertrophy over the entire study (n = 122): basal, stage I = at 12 months, stage II = at 24 months.
Table 2.
Clinical characteristics of patients with essential hypertension without left ventricular hypertrophy over the entire study (n = 98): basal, stage I = at 12 months, stage II = at 24 months.
Figure 2.
Bland-Altman plots for changes in NT-proBNP serum levels in hypertensive patients with hypertrophy.
Bland-Altman plot showing agreement between the logarithm of NT-proBNP levels percentage change against the average of the logarithm of NT-proBNP levels in basal + stage I (A), stage I + stage II (B) and basal + stage II (C). The solid line represents the mean of the percentage change. The dashed lines define the limits of agreement (standard deviation of percentage of change ×1.96 SD). NT-proBNP, N-terminal pro-brain natriuretic peptide levels; SD, standard deviation; stage I, 12-month follow-up; stage II, 24-month follow-up.
Figure 3.
Bland-Altman plots for changes in NT-proBNP serum levels in hypertensive patients without hypertrophy.
Bland-Altman plot showing agreement between the logarithm of NT-proBNP levels percentage change against the average of the logarithm of NT-proBNP levels in basal + stage I (A), stage I + stage II (B) and basal + stage II (C). The solid line represents the mean of the percentage change. The dashed lines define the limits of agreement (standard deviation of percentage of change ×1.96 SD). NT-proBNP, N-terminal pro-brain natriuretic peptide levels; SD, standard deviation; stage I, 12-month follow-up; stage II, 24-month follow-up.
Table 3.
Pearson's coefficient (r) between log-transformed serum NT-proBNP and inflammatory markers according to left ventricular hypertrophy over the entire study: basal, stage I = at 12 months, stage II = at 24 months.
Table 4.
Multivariate linear regression to evaluate the association of log-transformed NT-proBNP with inflammatory markers in hypertensive patients with hypertrophy.